癌变·畸变·突变 ›› 2009, Vol. 21 ›› Issue (1): 59-061.doi: 10.3969/j.issn.1004-616x.2009.01.014

• 论著 • 上一篇    下一篇

膀胱癌雌激素受体表达与他莫昔芬拮抗治疗的研究

朱 斌,杨罗艳,赵晓昆   

  1. 中南大学湘雅二医院泌尿外科,长沙 410011
  • 收稿日期:2008-08-27 修回日期:2008-10-19 出版日期:2009-01-30 发布日期:2009-01-30

A Study on the Expression of Estrogen Receptor and the Effect of Tamoxifen Treatment in Bladder Cancer

ZHU Bin,YANG Luo-yan,ZHAO Xiao-kun   

  1. Department of Urology,Xiangya 2nd Hospital of Central South University, Changsha 410011, China
  • Received:2008-08-27 Revised:2008-10-19 Online:2009-01-30 Published:2009-01-30

摘要: 背景与目的: 探讨他莫昔芬(TAM)联合阿霉素(ADM)对膀胱癌BIU-87细胞株生长的抑制作用。 材料与方法: 采用免疫组织化学法检测雌激素受体的表达;应用MTT法测定不同浓度的TAM(1、5、10 μmol/L)及ADM(0.1、1、10 μmol/L),单独和联合作用对BIU-87细胞的生长抑制率,观察TAM的增敏作用;采用原位杂交法检测各实验组bcl-2 mRNA的水平。 结果: 膀胱癌BIU-87细胞表达雌激素受体;TAM单独作用在低浓度时(1 μmol/L)对BIU-87生长无抑制作用;TAM联合ADM作用时,对BIU-87细胞生长的抑制率增加,其中TAM 10 μmol/L组增加显著(P<0.05),显示TAM能提高ADM的敏感性,起到化疗的增敏作用;随着TAM浓度的增加和时间的延长,BIU-87细胞bcl-2 mRNA的表达下调。 结论: 他莫昔芬能增加膀胱癌细胞株BIU-87对化疗药物ADM的敏感性,并抑制细胞增殖;其增敏的作用机制可能与bcl-2的表达下调有关。

关键词: 他莫昔芬, 膀胱肿瘤, bcl-2, 雌激素受体

Abstract: BACKGROUND AND AIM: In this study we tried to evaluate the possible effects on chemosensitization of bladder cancer cell line BIU-87. MATERIALS AND METHODS: The expression of estrogen receptor(ER) was evaluated by immunohistochemical S-P method.In vitro chemosensitivity tests were done with bladder cancer cell line BIU-87 and Doxorubicin(0.1,1,10 μmol/L) in the presence or absence of graded concentrations of Tamoxifen(1,5,10 μmol/L). The growth and the sensitivity to Tamoxifen of cells were investigated by MTT assay. The level of bcl-2 gene mRNA expression was determined by in situ hybridization. RESULTS: Immunohistochemistry showed positive ER in BIU-87 cells. Tamoxifen stimulated a concentration- dependent and time-dependent decrease in bcl-2 mRNA.Tamoxifen at concentrations of 5 and 10 μmol/L significantly enhanced the cytotoxicity of the chemotherapeutic agent to the cell lines. Tamoxifen alone caused significant toxic effects to BIU-87 at 10 μmol/L. Tamoxifen at 5 and 10 μmol/L down-regulated the secretion of bcl-2 in a concentration-dependent manner. The effect of chemosensitization was evident in cells treated with 1,5 and 10 μmol/L Tamoxifen plus Doxonubicin in which 1.77 to 6.96-fold IC50 reduction was observed. CONCLUSION: Tamoxifen increased the chemosensitivity of Tamoxifen in human bladder cancer BIU-87 cell line in vitro,inhibited cell proliferation and promoted apoptosis.

Key words: Tamoxifen, bladder neoplasms, bcl-2, estrogen receptor